Amgen fends off biosimilar for arthritis drug Enbrel
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Judge blocks sale of competitor for Amgen’s Enbrel
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
DA sues company over claims that product protects homes from fires
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
UC sues retailers over LED light patents by UCSB
The University of California is championing several UC Santa Barbara patents on the international stage, squaring off against retail giants like Amazon, Walmart and IKEA as it seeks to break new ground in protecting university research.
UC Regents, represented by law firm Nixon Peabody, filed a series of lawsuits and a complaint with the International Trade Commission in defense of intellectual property rights for filament LED technologies developed by UCSB researchers.
White: How to handle IRS efforts to collect unpaid taxes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
UCSB sues retailers for infringing LED light bulb patents
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: Capital and controversy mean cannabis here to stay
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
